Parkinsonism-Hyperpyrexia Syndrome During General Anesthesia: A Case Report.
Journal
A&A practice
ISSN: 2575-3126
Titre abrégé: A A Pract
Pays: United States
ID NLM: 101714112
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
13
8
2024
Statut:
epublish
Résumé
Parkinsonism-hyperpyrexia syndrome (PHS) is a rare, fatal complication of Parkinson's disease (PD) that manifests in patients who abruptly discontinue or reduce their antiParkinsonian medication. To the best of our knowledge, this is the first report of a PHS case occurring in a patient undergoing general anesthesia. In the perioperative period of PD patients, it is important for anesthesiologists to prevent PHS as well as monitor patients to enable early detection and prompt response when it occurs.
Identifiants
pubmed: 39137104
doi: 10.1213/XAA.0000000000001840
pii: 02054229-202408000-00006
doi:
Substances chimiques
Antiparkinson Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e01840Informations de copyright
Copyright © 2024 International Anesthesia Research Society.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Meagher LJ, McKay D, Herkes GK, Needham M. Parkinsonism–hyperpyrexia syndrome: the role of electroconvulsive therapy. J Clin Neurosci. 2006;13:857–859.
Newman EJ, Grosset DG, Kennedy PGE. The Parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10:136–140.
Wang J-Y, Huang J-F, Zhu S-G, et al. Parkinsonism-hyperpyrexia syndrome and dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: two cases and literature review. J Parkinsons Dis. 2022;12:1727–1735.
Kodama S, Jo T, Yasunaga H, et al. Perioperative use of intravenous levodopa as an anti-Parkinsonian drug: a propensity score analysis. Mov Disord Clin Pract. 2023;10:1650–1658.
Shaikh N, Saadeddin A. Parkinsonism-hyperpyrexia syndrome in a patient undergoing upper gastrointestinal surgery: a case report. Qatar Med J. 2024;2023:34.
Japanese Society of Neurology. Guideline for Parkinson’s Disease. Igaku-Shoin; 2018.
Safety Committee of Japanese Society of Anesthesiologists. JSA guideline for the management of malignant hyperthermia crisis 2016. J Anesth. 2017;31:307–317.
Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771–779.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.